Valneva Announces Phase 2 Trials Of Lyme Disease Vaccine Candidate, VLA15 Have Been Published In 'The Lancet Infectious Diseases'
Author: Benzinga Newsdesk | June 03, 2024 11:46am
Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease vaccine candidate, VLA15, were published in the peer-reviewed medical journal, The Lancet Infectious Diseases. These trials, as well as a third Phase 2 trial in pediatric participants, supported the design of the current pivotal Phase 3 trial, ‘Vaccine Against Lyme for Outdoor Recreationists' (VALOR).
Posted In: PARIS:VLA VALN